Yap TA, Gainor JF, Callahan MK, Falchook GS, et al. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. Clin Cancer Res 2022;28:3695-3708.
PMID: 35511938